- Record: found
- Abstract: not found
- Article: not found
ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir/pibrentasvir (formerly ABT-493/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis
S. ZEUZEM, J. Feld, S Wang, M Bourliere, H Wedemeyer, E. GANE, R. Flisiak, WL CHUANG, S. FLAMM, P Kwo, G Sepulveda-Arzola, R Soto-Malave, M Puoti, E Tam, R Bruck, F. FUSTER, SW Paik, F Felizarta, B FU, TI Ng, CW LIN, F Mensa
2016
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.